| 9.15 0.28 (3.16%) | 12-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.9 | 1-year : | 12.74 |
| Resists | First : | 9.34 | Second : | 10.9 |
| Pivot price | 8.2  |
|||
| Supports | First : | 7.59 | Second : | 6.51 |
| MAs | MA(5) : | 8.81 |
MA(20) : | 7.95 |
| MA(100) : | 7.27 |
MA(250) : | 8.07 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 88.2 |
D(3) : | 90.6 |
| RSI | RSI(14): 77.4 |
|||
| 52-week | High : | 10.8 | Low : | 5.76 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ZYME ] has closed below upper band by 7.1%. Bollinger Bands are 102.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.18 - 9.21 | 9.21 - 9.24 |
| Low: | 8.64 - 8.67 | 8.67 - 8.71 |
| Close: | 9.09 - 9.14 | 9.14 - 9.2 |
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Fri, 01 Dec 2023
Does Zymeworks Inc. (ZYME) Have the Potential to Rally 42.84% as ... - Yahoo Finance
Thu, 30 Nov 2023
Zymeworks Announces Participation in Upcoming Investor Conference - Yahoo Finance
Wed, 15 Nov 2023
Wall Street Analysts Predict a 64.61% Upside in Zymeworks Inc ... - Nasdaq
Sun, 12 Nov 2023
Validea's Top Health Care Stocks Based On Benjamin Graham - 11 ... - Nasdaq
Wed, 08 Nov 2023
Zymeworks Inc. (NYSE:ZYME) Q3 2023 Earnings Call Transcript - Yahoo Finance
Wed, 01 Nov 2023
Zymeworks Announces Participation in Upcoming Investor Conferences - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 70 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 4.8 (%) |
| Held by Institutions | 96.4 (%) |
| Shares Short | 2,420 (K) |
| Shares Short P.Month | 4,680 (K) |
| EPS | 3.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.25 |
| Profit Margin | 44.4 % |
| Operating Margin | -201.3 % |
| Return on Assets (ttm) | 29.7 % |
| Return on Equity (ttm) | 67.9 % |
| Qtrly Rev. Growth | 527.4 % |
| Gross Profit (p.s.) | 2.91 |
| Sales Per Share | 6.59 |
| EBITDA (p.s.) | 3.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 195 (M) |
| Levered Free Cash Flow | 111 (M) |
| PE Ratio | 2.83 |
| PEG Ratio | -0.4 |
| Price to Book value | 1.46 |
| Price to Sales | 1.38 |
| Price to Cash Flow | 3.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|